Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors
Sponsor: Vir Biotechnology, Inc.
A PHASE1 clinical study on Chronic Hepatitis B, this trial is ongoing. The trial is conducted by Vir Biotechnology, Inc. and has accumulated 6 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — Jun 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vir Biotechnology, Inc.
- Virion Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .